Triple-negative breast cancer (TNBC) accounts for ~10–20% of all patients with breast cancer and is traditionally defined by the lack of expression of the estrogen and progesterone receptors, alongside no overexpression or amplification of the human epidermal growth factor receptor 2 (HER2)1. Here, ERBB2 is linked to triple-negative breast carcinoma.